Shares of Arena hit a 52-week high on Tuesday of $7.75. The stock's 52-week low of $1.23 was set on Oct. 4."Arena raised gross proceeds of $69.6 million bringing pro forma cash to ~$154 million, which we estimate is sufficient to gain Lorcaserin approval," Piper Jaffray analysts wrote in a May 29 report. "Earlier this month, the Endocrinologic and Metabolic Drugs Advisory Committee voted 18 to 4 to approve Lorcaserin for the treatment of obesity. The drug's PDUFA date is June 27th, but could potentially be pushed back 90 days. Regardless, we do anticipate approval this year triggering a $60 million milestone from partner Eisai. We reiterate our Overweight rating and $7 price target." Five of the 11 analysts who cover Arena rated it hold. Four analysts gave the stock a buy rating and two rated it sell. The stock has risen 311.81% year to date. -- Written by Alexandra Zendrian
>To contact the writer of this article, click here: Alexandra Zendrian >To submit a news tip, send an email to: firstname.lastname@example.org. >To follow the writer on Twitter, go to Alexandra Zendrian.